Hepatosplenic gamma-delta T-cell lymphoma: Clinicopathological features and treatment

G. S. Falchook, Francisco Vega, N. H. Dang, F. Samaniego, M. A. Rodriguez, R. E. Champlin, C. Hosing, S. Verstovsek, B. Pro

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined. Methods: We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed. Results: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain. Conclusion: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.

Original languageEnglish
Pages (from-to)1080-1085
Number of pages6
JournalAnnals of Oncology
Volume20
Issue number6
DOIs
StatePublished - Jun 4 2009
Externally publishedYes

Fingerprint

Somatostatin-Secreting Cells
T-Cell Lymphoma
Therapeutics
T-Lymphocyte Gene Rearrangement
Peripheral T-Cell Lymphoma
T-Cell Receptor Genes
Drug Therapy
Survival
Anthracyclines
Hematopoietic Stem Cell Transplantation
Databases
Population

Keywords

  • Clinicopathological features
  • Hematopoietic stem-cell transplantation
  • Hepatosplenic T-cell lymphoma
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Falchook, G. S., Vega, F., Dang, N. H., Samaniego, F., Rodriguez, M. A., Champlin, R. E., ... Pro, B. (2009). Hepatosplenic gamma-delta T-cell lymphoma: Clinicopathological features and treatment. Annals of Oncology, 20(6), 1080-1085. https://doi.org/10.1093/annonc/mdn751

Hepatosplenic gamma-delta T-cell lymphoma : Clinicopathological features and treatment. / Falchook, G. S.; Vega, Francisco; Dang, N. H.; Samaniego, F.; Rodriguez, M. A.; Champlin, R. E.; Hosing, C.; Verstovsek, S.; Pro, B.

In: Annals of Oncology, Vol. 20, No. 6, 04.06.2009, p. 1080-1085.

Research output: Contribution to journalArticle

Falchook, GS, Vega, F, Dang, NH, Samaniego, F, Rodriguez, MA, Champlin, RE, Hosing, C, Verstovsek, S & Pro, B 2009, 'Hepatosplenic gamma-delta T-cell lymphoma: Clinicopathological features and treatment', Annals of Oncology, vol. 20, no. 6, pp. 1080-1085. https://doi.org/10.1093/annonc/mdn751
Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE et al. Hepatosplenic gamma-delta T-cell lymphoma: Clinicopathological features and treatment. Annals of Oncology. 2009 Jun 4;20(6):1080-1085. https://doi.org/10.1093/annonc/mdn751
Falchook, G. S. ; Vega, Francisco ; Dang, N. H. ; Samaniego, F. ; Rodriguez, M. A. ; Champlin, R. E. ; Hosing, C. ; Verstovsek, S. ; Pro, B. / Hepatosplenic gamma-delta T-cell lymphoma : Clinicopathological features and treatment. In: Annals of Oncology. 2009 ; Vol. 20, No. 6. pp. 1080-1085.
@article{62911e559cfb4c14862f4099a7bf3c96,
title = "Hepatosplenic gamma-delta T-cell lymphoma: Clinicopathological features and treatment",
abstract = "Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined. Methods: We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed. Results: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain. Conclusion: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.",
keywords = "Clinicopathological features, Hematopoietic stem-cell transplantation, Hepatosplenic T-cell lymphoma, Treatment",
author = "Falchook, {G. S.} and Francisco Vega and Dang, {N. H.} and F. Samaniego and Rodriguez, {M. A.} and Champlin, {R. E.} and C. Hosing and S. Verstovsek and B. Pro",
year = "2009",
month = "6",
day = "4",
doi = "10.1093/annonc/mdn751",
language = "English",
volume = "20",
pages = "1080--1085",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Hepatosplenic gamma-delta T-cell lymphoma

T2 - Clinicopathological features and treatment

AU - Falchook, G. S.

AU - Vega, Francisco

AU - Dang, N. H.

AU - Samaniego, F.

AU - Rodriguez, M. A.

AU - Champlin, R. E.

AU - Hosing, C.

AU - Verstovsek, S.

AU - Pro, B.

PY - 2009/6/4

Y1 - 2009/6/4

N2 - Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined. Methods: We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed. Results: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain. Conclusion: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.

AB - Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined. Methods: We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed. Results: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain. Conclusion: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.

KW - Clinicopathological features

KW - Hematopoietic stem-cell transplantation

KW - Hepatosplenic T-cell lymphoma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=66149096620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149096620&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn751

DO - 10.1093/annonc/mdn751

M3 - Article

C2 - 19237479

AN - SCOPUS:66149096620

VL - 20

SP - 1080

EP - 1085

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -